These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 2242520)

  • 1. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis.
    Waters D; Lespérance J; Francetich M; Causey D; Théroux P; Chiang YK; Hudon G; Lemarbre L; Reitman M; Joyal M
    Circulation; 1990 Dec; 82(6):1940-53. PubMed ID: 2242520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long term effects of nisoldipine on the progression of coronary atherosclerosis and the occurrence of clinical events: the NICOLE study.
    Dens JA; Desmet WJ; Coussement P; De Scheerder IK; Kostopoulos K; Kerdsinchai P; Supanantaroek C; Piessens JH
    Heart; 2003 Aug; 89(8):887-92. PubMed ID: 12860866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International nifedipine trial on anti-atherosclerotic therapy (INTACT)--methodologic implications and results of a coronary angiographic follow-up study using computer-assisted film analysis.
    Jost S; Deckers J; Rafflenbeul W; Hecker H; Reiber JH; Nikutta P; Wiese B; Hugenholtz P; Lichtlen P
    Int J Card Imaging; 1990-1991; 6(2):117-33. PubMed ID: 2097305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute effects of nicardipine and esmolol on the cardiac cycle, intracardiac hemodynamic and endothelial shear stress in patients with unstable angina pectoris and moderate coronary stenosis: results from single center, randomized study.
    Chen SL; Hu ZY; Zhang JJ; Ye F; Kan J; Xu T; Liu ZZ; Zhang YJ; Zhang JX; Chen M
    Cardiovasc Ther; 2012 Jun; 30(3):162-71. PubMed ID: 22099625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.
    Waters D; Higginson L; Gladstone P; Kimball B; Le May M; Boccuzzi SJ; Lespérance J
    Circulation; 1994 Mar; 89(3):959-68. PubMed ID: 8124836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of cigarette smoking on the angiographic evolution of coronary atherosclerosis. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy. CCAIT Study Group.
    Waters D; Lespérance J; Gladstone P; Boccuzzi SJ; Cook T; Hudgin R; Krip G; Higginson L
    Circulation; 1996 Aug; 94(4):614-21. PubMed ID: 8772679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial.
    Nissen SE; Tuzcu EM; Libby P; Thompson PD; Ghali M; Garza D; Berman L; Shi H; Buebendorf E; Topol EJ;
    JAMA; 2004 Nov; 292(18):2217-25. PubMed ID: 15536108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of progression of coronary atherosclerosis.
    Waters D; Craven TE; Lespérance J
    Circulation; 1993 Apr; 87(4):1067-75. PubMed ID: 8484829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium channel blockers and coronary atherosclerosis: from the rabbit to the real world.
    Waters D; Lespérance J
    Am Heart J; 1994 Dec; 128(6 Pt 2):1309-16. PubMed ID: 7977012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design features of a controlled clinical trial to assess the effect of a calcium entry blocker upon the progression of coronary artery disease.
    Waters D; Freedman D; Lesperance J; Theroux P; Lemarbre L; Kamm B; Joyal M; Dyrda I; Gosselin G; Hudon G
    Control Clin Trials; 1987 Sep; 8(3):216-42. PubMed ID: 3665523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised comparison of the effects of nicardipine and esmolol on coronary artery wall stress: implications for the risk of plaque rupture.
    Williams MJ; Low CJ; Wilkins GT; Stewart RA
    Heart; 2000 Oct; 84(4):377-82. PubMed ID: 10995404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators.
    Pitt B; Byington RP; Furberg CD; Hunninghake DB; Mancini GB; Miller ME; Riley W
    Circulation; 2000 Sep; 102(13):1503-10. PubMed ID: 11004140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Modification of coronary arteriosclerosis in man by calcium antagonists?].
    Schneider W; Roebruck P; Cieslinski G; Noack H; Kober G; Alle M; Kaltenbach M
    Z Kardiol; 1991; 80 Suppl 9():63-71. PubMed ID: 1796651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retardation of coronary artery disease in humans by the calcium-channel blocker nifedipine: results of the INTACT study (International Nifedipine Trial on Antiatherosclerotic Therapy).
    Lichtlen PR; Hugenholtz PG; Rafflenbeul W; Hecker H; Jost S; Nikutta P; Deckers JW
    Cardiovasc Drugs Ther; 1990 Aug; 4 Suppl 5():1047-68. PubMed ID: 2076392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interventions that beneficially influence the evolution of coronary atherosclerosis. The case for calcium channel blockers.
    Waters D; Lespérance J
    Circulation; 1992 Dec; 86(6 Suppl):III111-6. PubMed ID: 1424044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concept of an antiatherosclerotic efficacy of calcium entry blockers. INTACT Investigators.
    Jost S; Rafflenbeul W; Deckers J; Wiese B; Hecker H; Nikutta P; Lippolt P; Lichtlen P
    Eur J Epidemiol; 1992 May; 8 Suppl 1():107-19. PubMed ID: 1505647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous injection of nicardipine changed the distribution of coronary artery endothelial shear stress and fluid dynamics in patients with unstable angina.
    Chen SL; Hu ZY; Zhang JJ; Kan J; Xu T; Liu ZZ; Xu HM
    Chin Med J (Engl); 2012 Sep; 125(18):3240-5. PubMed ID: 22964316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design features of a controlled clinical trial to assess the effect of an HMG CoA reductase inhibitor on the progression of coronary artery disease. Canadian Coronary Atherosclerosis Intervention Trial Investigators Montreal, Ottawa, and Toronto, Canada.
    Waters D; Higginson L; Gladstone P; Kimball B; LeMay M; Lespérance J
    Control Clin Trials; 1993 Feb; 14(1):45-74. PubMed ID: 8440094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retardation of development and progression of coronary atherosclerosis: a new indication for calcium antagonists?
    Schneider W; Kober G; Roebruck P; Noack H; Alle M; Cieslinski G; Reifart N; Kaltenbach M
    Eur J Clin Pharmacol; 1990; 39 Suppl 1():S17-23. PubMed ID: 2261941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Is regression of coronary sclerosis possible?].
    Krayenbühl HP
    Schweiz Rundsch Med Prax; 1993 Nov; 82(47):1348-53. PubMed ID: 8272700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.